Short answer
GRAIL, Inc. (GRAL) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). GRAIL announced financial results for Q3 ended September 30, 2026.
GRAIL, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- GRAIL announced financial results for Q3 ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, cash flow and guidance details
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $37.5M, up 4%, led by Galleri revenue growth of 14% to $37.3M
- Galleri volume exceeded 56,000 tests, up approximately 24%; nine-month volume surpassed 174,000, up 36%
- FDA Advisory Committee favorable vote supports potential approval, with FDA decision anticipated by early Q1 2027
- Profitability deteriorated: net loss $103.6M, adjusted EBITDA loss $92.6M, adjusted gross margin 42% versus 55%
- Liquidity totaled $788.7M, providing funding capacity despite $307.0M nine-month net loss
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GRAIL, Inc. 8-K filings
Get the next GRAL 8-K as it lands
Follow GRAL for push alerts, or ask the research agent what this filing means.